<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="editorial" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1108263</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.1108263</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Editorial</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Methods and applications in inflammation pharmacology</article-title>
<alt-title alt-title-type="left-running-head">Schmidtchen et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2022.1108263">10.3389/fphar.2022.1108263</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Schmidtchen</surname>
<given-names>Artur</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/563769/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mirza</surname>
<given-names>Haris</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1703382/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van der Plas</surname>
<given-names>Mariena J. A.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/341615/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nadeem</surname>
<given-names>Aftab</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/286060/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Puthia</surname>
<given-names>Manoj</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/574642/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Division of Dermatology and Venereology</institution>, <institution>Department of Clinical Sciences</institution>, <institution>Lund University</institution>, <addr-line>Lund</addr-line>, <country>Sweden</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Copenhagen Wound Healing Center</institution>, <institution>Bispebjerg Hospital</institution>, <institution>Department of Biomedical Sciences</institution>, <institution>University of Copenhagen</institution>, <addr-line>Copenhagen</addr-line>, <country>Denmark</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Immunobiology</institution>, <institution>Yale University School of Medicine</institution>, <addr-line>New Haven</addr-line>, <addr-line>CT</addr-line>, <country>United States</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Pharmacy</institution>, <institution>University of Copenhagen</institution>, <addr-line>Copenhagen</addr-line>, <country>Denmark</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Department of Molecular Biology</institution>, <institution>Ume&#xe5; University</institution>, <addr-line>Ume&#xe5;</addr-line>, <country>Sweden</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited and reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/10035/overview">Paola Patrignani</ext-link>, University of Studies G d&#x27;Annunzio Chieti and Pescara, Italy</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Manoj Puthia, <email>manoj.puthia@med.lu.se</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>1108263</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>11</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>12</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Schmidtchen, Mirza, van der Plas, Nadeem and Puthia.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Schmidtchen, Mirza, van der Plas, Nadeem and Puthia</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" journal-id="Front. Pharmacol." related-article-type="commentary-article" xlink:href="https://www.frontiersin.org/researchtopic/32199" ext-link-type="uri">Editorial on the Research Topic <article-title>Methods and applications in inflammation pharmacology</article-title>
</related-article>
<kwd-group>
<kwd>inflammation</kwd>
<kwd>pharmacology</kwd>
<kwd>innate immunity</kwd>
<kwd>preclinical</kwd>
<kwd>animal models</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The body has its own ways of defending itself and responding to insults (<xref ref-type="bibr" rid="B4">Delves and Roitt, 2000</xref>). Inflammation is one of the most vital biological responses of the immune system. In the body, inflammation can be triggered by various harmful stimuli such as pathogens, toxins, tissue damage, radiation, and autoimmune disorders. The inflammatory process can be acute or chronic in nature and it can affect vital organs and other tissue compartments. Although inflammation is mostly beneficial, excessive inflammation can lead to discomfort, loss of function of organs, and even death (<xref ref-type="bibr" rid="B3">Chen et al., 2018</xref>; <xref ref-type="bibr" rid="B5">Furman et al., 2019</xref>). The immune system mostly knows how to respond judiciously but sometimes does not know how much to respond, leading to uncontrolled inflammation. During these circumstances of uncontrolled inflammation, pharmacological interventions are needed. Novel interventions, for example, may include the precision medicine (<xref ref-type="bibr" rid="B2">Ashley, 2016</xref>), targeted delivery (<xref ref-type="bibr" rid="B14">Srinivasarao and Low, 2017</xref>), RNA-based therapies (<xref ref-type="bibr" rid="B6">Guo et al., 2016</xref>; <xref ref-type="bibr" rid="B16">Zhu et al., 2022</xref>), therapeutic host defense peptides (<xref ref-type="bibr" rid="B9">Mookherjee et al., 2020</xref>; <xref ref-type="bibr" rid="B12">Puthia et al., 2020</xref>), and innate immune modulation (<xref ref-type="bibr" rid="B7">Kanzler et al., 2007</xref>; <xref ref-type="bibr" rid="B11">Puthia et al., 2016</xref>). A variety of cell culture models, reporter assays, and animal models including transgenic and humanized mouse models play a key role in studying the molecular mechanisms of inflammation (<xref ref-type="bibr" rid="B1">Allen et al., 2019</xref>). Robust screening methods and relevant translatable disease models are being used for the development of new therapies and preclinical testing (<xref ref-type="bibr" rid="B15">Wirtz et al., 2017</xref>; <xref ref-type="bibr" rid="B10">Patil et al., 2019</xref>). State-of-the-art molecular imaging of inflammation, such as Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), or Magnetic resonance imaging (MRI) is being used to improve our understanding of the pathophysiology of diseases. Longitudinal <italic>in vivo</italic> bioluminescence and fluorescence imaging has become widely used tool for studying the inflammation process in laboratory animals (<xref ref-type="bibr" rid="B8">Mezzanotte et al., 2017</xref>; <xref ref-type="bibr" rid="B13">Schmidtchen and Puthia, 2020</xref>).</p>
<p>This special Research Topic &#x2018;Methods and Applications in Inflammation Pharmacology: 2022 focuses on pharmacological interventions and state-of-the-art methods during inflammatory conditions. A total of five original articles and one review were published.</p>
<p>Dandelions (<italic>Taraxacum</italic> spp.) have been used as a medicinal herb for a long time. Dandelions contain various bioactive substances which are reported to have pharmacological properties. Li et al. investigated the anti-inflammatory effects of Dandelion extract in LPS-induced RAW264.7 macrophages and copper sulfate (CuSO4)-induced zebrafish larvae. The dandelion extract reduced the LPS-induced inflammatory response in RAW264.7 cells by regulating polarization and apoptosis. Showing a therapeutic potential, the dandelion extract also reduced the CuSO<sub>4</sub>-induced inflammatory response in zebrafish larvae (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.906927/full">Li et al.</ext-link>).</p>
<p>Icariin, a flavonoid compound isolated from plants of the <italic>Epimedium genus</italic>, has shown anti-inflammatory, immunoregulatory, and antibacterial properties. Li et al. investigated the effects of icariin on inflammation-associated intestinal barrier function impairment and showed that it attenuated the expressions of Occludin, Claudin1, and Claudin5 in rat colon (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.903762/full">Li et al.</ext-link>). Icariin alleviated TNF-&#x3b1;-induced Occludin disruption and epithelial barrier impairment by decreasing miR-122a expression in Caco-2 cell monolayers. In another study, <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.937502/full">Shao et al.</ext-link> demonstrated that icariin protects against cartilage endplate degeneration and calcification under intervertebral disc degeneration conditions, and the associated mechanism may be related to Nrf-2/HO-1 mediated mitophagy activation and ferroptosis inhibition (Shao et al.). Both of these studies show the therapeutic potential of icariin during inflammatory disorders.</p>
<p>Chen G. et al. Investigated the therapeutic potential of active component formulation (ACF) from Huanglian Jiedu Decoction during LPS-induced systemic inflammation. ACF components showed a good binding ability to MD-2 and ACF treatment reduced inflammatory cell infiltration and organ damage in rat LPS-induced sepsis model (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.947095/fulll">Chen et al.</ext-link>).</p>
<p>In another study, Ahsan et al. showed that <italic>Saussuria lappa</italic> extract has immunomodulatory effects and reduced the number of colonizing bacteria in the liver, spleen, and lungs and also lowered the levels of neutrophils and interleukin eight in <italic>Acinetobacter baumannii</italic> mouse infection model (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.986802/fulll">Ahsan et al.</ext-link>). Finally, Xiao et al. reviewed the role of inhibitor of nuclear factor kappa-B kinase &#x3b5; (IKK&#x3b5;) in metabolic diseases and summarized the structural characterization, physiological function, and pathological role of IKK&#x3b5; in metabolic diseases, and discussed small molecule inhibitors of IKK&#x3b5; (<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2022.888588/fulll">Xiao et al.</ext-link>).</p>
</body>
<back>
<sec id="s1">
<title>Author contributions</title>
<p>All authors have made a significant, direct, or intellectual contribution to the article.</p>
</sec>
<sec sec-type="COI-statement" id="s2">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s3">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Brehm</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Bridges</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mirochnitchenko</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Humanized immune system mouse models: Progress, challenges and opportunities</article-title>. <source>Nat. Immunol.</source> <volume>20</volume>, <fpage>770</fpage>&#x2013;<lpage>774</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-019-0416-z</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashley</surname>
<given-names>E. A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Towards precision medicine</article-title>. <source>Nat. Rev. Genet.</source> <volume>17</volume>, <fpage>507</fpage>&#x2013;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1038/nrg.2016.86</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Inflammatory responses and inflammation-associated diseases in organs</article-title>. <source>Oncotarget</source> <volume>9</volume>, <fpage>7204</fpage>&#x2013;<lpage>7218</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.23208</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delves</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Roitt</surname>
<given-names>I. M.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>The immune system. First of two parts</article-title>. <source>N. Engl. J. Med.</source> <volume>343</volume>, <fpage>37</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM200007063430107</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Campisi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Verdin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Carrera-Bastos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Targ</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Franceschi</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Chronic inflammation in the etiology of disease across the life span</article-title>. <source>Nat. Med.</source> <volume>25</volume>, <fpage>1822</fpage>&#x2013;<lpage>1832</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-019-0675-0</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gui</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>RNA interference-based nanosystems for inflammatory bowel disease therapy</article-title>. <source>Int. J. Nanomedicine</source> <volume>11</volume>, <fpage>5287</fpage>&#x2013;<lpage>5310</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S116902</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanzler</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Barrat</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Hessel</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Coffman</surname>
<given-names>R. L.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists</article-title>. <source>Nat. Med.</source> <volume>13</volume>, <fpage>552</fpage>&#x2013;<lpage>559</lpage>. <pub-id pub-id-type="doi">10.1038/nm1589</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mezzanotte</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Van &#x27;T Root</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karatas</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Goun</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Lowik</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>
<italic>In vivo</italic> molecular bioluminescence imaging: New tools and Applications</article-title>. <source>Trends Biotechnol.</source> <volume>35</volume>, <fpage>640</fpage>&#x2013;<lpage>652</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibtech.2017.03.012</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mookherjee</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Haagsman</surname>
<given-names>H. P.</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Antimicrobial host defence peptides: Functions and clinical potential</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>19</volume>, <fpage>311</fpage>&#x2013;<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-019-0058-8</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patil</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Mahajan</surname>
<given-names>U. B.</given-names>
</name>
<name>
<surname>Unger</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Belemkar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Surana</surname>
<given-names>S. J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Animal models of inflammation for screening of anti-inflammatory drugs: Implications for the discovery and development of phytopharmaceuticals</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume>, <fpage>4367</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20184367</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puthia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ambite</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cafaro</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lutay</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>IRF7 inhibition prevents destructive innate immunity-A target for nonantibiotic therapy of bacterial infections</article-title>. <source>Sci. Transl. Med.</source> <volume>8</volume>, <fpage>336ra59</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aaf1156</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puthia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Butrym</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Petrlova</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stromdahl</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Kjellstrom</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>A dual-action peptide-containing hydrogel targets wound infection and inflammation</article-title>. <source>Sci. Transl. Med.</source> <volume>12</volume>, <fpage>eaax6601</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aax6601</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidtchen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Puthia</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Real-time <italic>in vivo</italic> imaging of LPS-induced local inflammation and drug deposition in NF-&#x3ba;B reporter mice</article-title>. <source>Bio. Protoc.</source> <volume>10</volume>, <fpage>e3724</fpage>. <pub-id pub-id-type="doi">10.21769/BioProtoc.3724</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasarao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>P. S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Ligand-targeted drug delivery</article-title>. <source>Chem. Rev.</source> <volume>117</volume>, <fpage>12133</fpage>&#x2013;<lpage>12164</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.7b00013</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wirtz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Popp</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kindermann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gerlach</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Weigmann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Fichtner-Feigl</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Chemically induced mouse models of acute and chronic intestinal inflammation</article-title>. <source>Nat. Protoc.</source> <volume>12</volume>, <fpage>1295</fpage>&#x2013;<lpage>1309</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2017.044</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>RNA-Based therapeutics: An overview and prospectus</article-title>. <source>Cell Death Dis.</source> <volume>13</volume>, <fpage>644</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-022-05075-2</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>